The combination of talazoparib (Talzenna) and enzalutamide (Xtandi) significantly improved radiographic progression-free survival (rPFS) in patients with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC) in the Phase III TALAPRO-3 trial. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression or death compared with enzalutamide alone. Consistent benefit was observed across key subgroups, including both BRCA and non-BRCA HRR alterations, supporting the potential for earlier integration of PARP inhibition in biomarker-selected patients.

Clinical Takeaway

Talazoparib plus enzalutamide significantly improves rPFS in patients with HRR gene-mutated mCSPC, with consistent benefit across both BRCA and non-BRCA alterations. These findings support earlier integration of PARP inhibition in biomarker-selected patients and highlight the growing importance of upfront genomic testing to guide first-line treatment strategies.

Drug Profile & Mechanism

  • Agent:
    • talazoparib (Talzenna)
    • enzalutamide (Xtandi)
  • Class & Mechanism of action:
    • talazoparib: Poly (ADP-ribose) polymerase (PARP) inhibitor that blocks PARP enzyme activity and induces PARP trapping at sites of DNA damage, leading to impaired DNA repair and accumulation of double-strand breaks, particularly in homologous recombination repair (HRR)-deficient tumors
    • enzalutamide: Androgen receptor pathway inhibitor that blocks androgen binding, nuclear translocation, and transcriptional activity, suppressing prostate cancer cell growth
  • Combination Rationale:
    • Dual targeting of androgen receptor signaling and DNA repair pathways exploits synthetic lethality in HRR-deficient tumors, enhancing antitumor activity and delaying disease progression
  • Route of administration & Dosing Schedule:
    • talazoparib: Oral, once daily
    • enzalutamide: Oral, once daily

Target Population

  • Patients with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), including those with BRCA and non-BRCA HRR alterations, who are candidates for androgen receptor pathway inhibitor-based therapy in the first-line metastatic setting.

Phase III TALAPRO-3 Study Design (NCT04821622)

  • Study Type: Phase III, randomized, double-blind, placebo-controlled, multicenter trial
  • Population: 599 patients with histologically confirmed metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations, with ≤3 months of prior androgen deprivation therapy (ADT) with or without a prior androgen receptor pathway inhibitor (ARPI)
  • Comparator: Placebo plus enzalutamide
  • Treatment Regimen: talazoparib 0.5 mg orally once daily plus enzalutamide 160 mg orally once daily versus placebo plus enzalutamide
  • Follow-Up Duration: Not yet reported (interim analysis)
  • Primary Completion Date: February 18, 2026
  • Estimated study completion: August 28, 2027

Endpoints

  • Primary Endpoint:
    • Radiographic progression-free survival (rPFS), defined as time from randomization to radiographic disease progression (per RECIST 1.1 for soft tissue or PCWG3 criteria for bone) or death from any cause
  • Key Secondary Endpoints:
    • Overall survival (OS)
    • Objective response rate (ORR)
    • Duration of response (DoR)
    • Time to prostate-specific antigen (PSA) progression
    • Patient-reported outcomes

Efficacy Outcomes

  • Primary Endpoint Results:
    • Talazoparib plus enzalutamide demonstrated a statistically significant and clinically meaningful improvement in rPFS compared with placebo plus enzalutamide. The combination exceeded the prespecified hazard ratio target, with the majority of patients remaining progression-free at the time of analysis.
  • Secondary Endpoint Results:
    • Consistent rPFS benefit was observed across key subgroups, including patients with both BRCA and non-BRCA HRR gene alterations. Improvements were also reported in ORR, DoR, and time to PSA progression.
  • Overall Survival:
    • OS (Final Analysis): Not yet reported
    • Median OS: Not yet reported
    • Hazard ratio for death: Not yet reported

Regulatory Milestones

  • Approval Status:
    • Talazoparib plus enzalutamide is currently approved for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer; use in mCSPC remains investigational
  • Regulatory Pathway: Positive Phase III TALAPRO-3 results support potential regulatory submissions to expand the indication into the mCSPC setting
  • Regulatory Review: Results are expected to be presented at an upcoming medical meeting and will be discussed with global health authorities

Safety

  • Overall Safety Profile: Consistent with known safety profiles of each agent, with no new safety signals identified
  • Grade ≥3 Events:
    • Not fully reported; consistent with the known hematologic and treatment-related toxicities associated with PARP inhibition and androgen receptor pathway inhibition
  • Treatment-related deaths: Not reported in the interim analysis
  • Notable toxicity patterns:
    • Safety findings were consistent with prior experience, including expected hematologic toxicities (e.g., anemia, neutropenia, thrombocytopenia) associated with talazoparib

Key Clinical Implications

✔ Talazoparib plus enzalutamide demonstrates clinically meaningful rPFS improvement in HRR-mutated mCSPC, supporting earlier intensification of therapy in a high-risk, biomarker-defined population

✔ Consistent efficacy across both BRCA and non-BRCA HRR alterations suggests broader applicability beyond traditional BRCA-focused PARP inhibitor use

✔ These findings support routine HRR genomic testing at diagnosis of metastatic prostate cancer to guide first-line treatment decisions

✔ The combination builds on an established standard of care in mCRPC and may shift PARP inhibitor use into earlier disease settings

✔ Pending overall survival data and regulatory review, this regimen has the potential to redefine first-line management for patients with HRR-mutated mCSPC

Bottom Line

The Phase III TALAPRO-3 trial demonstrates that combining talazoparib with enzalutamide significantly delays disease progression in HRR-mutated mCSPC, extending the benefit of PARP inhibition into an earlier disease setting. With consistent efficacy across HRR subgroups and a manageable safety profile, this combination has the potential to reshape first-line treatment strategies pending OS maturity and regulatory review.

Sources: